U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06793917) titled 'Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma' on Jan. 21.
Brief Summary: To compare the efficacy and safety of tislelizumab combined with FOLFOX or combined with POF in the treatment of locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma with CPS>=1
Study Start Date: April 01, 2025
Study Type: INTERVENTIONAL
Condition:
Gastric Cancer
Intervention:
DRUG: Tislelizumab
Tislelizumab will be administered on day 1 of each cycle at 200mg...